Page 3 - Advanced Head News Today

Nanobiotix Announces Key Development Milestones for 2021 After Successful Nasdaq Initial Public Offering Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registration study in head and neck cancer in the United States in 2021 Following previously reported preliminary data regarding the ability of NBTXR3 to help transform anti-PD-1 non-responders into responders, the Company will provide the next update on its immuno-oncology phase I basket study eval...